Skin cancer is the most common malignancy in fair-skinned populations, with melanoma incidence the highest in New Zealand and Australia (50 and 48 per 100 000 population, respectively) and projected to increase in the UK (from 17 to 36 per 100 000 population) and in the USA (from 29 to 32 per 100 000 population) between 2007–11 and 2022–26.1 Non-melanoma skin cancer is up to 20 times more common than melanoma worldwide.2 For every melanoma diagnosed, there are from three to 40 benign lesions biopsied; the proportion of biopsied lesions that are benign is generally greater in primary care than in specialist settings.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qyLkwD
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidiscip...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
Abstract Soil conditioners can be used to compensate for the insufficient soil nutrition and organic matter (OM) of arable soils. However, ...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Ocular Vestibular Evoked Myogenic Potentials: Where Are We Now? Objective: Over the last decade, ocular vestibular evoked myogenic potential...
-
Related Articles Screening for Atrial Fibrillation using Economical and accurate TechnologY (SAFETY)-a pilot study. BMJ Open. 2017 Ja...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
Publication date: Available online 6 January 2018 Source: Current Problems in Diagnostic Radiology Author(s): Mark D. Kovacs, Maximilian...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου